Replies to post #259193 on Avid Bioservices Inc (CDMO)

[pphmtoolong]

While I strongly feel Peregrine needs to scale back Bavi development, I do hope the AstraZeneca collaboration can go forward.

If Bavi can work well with AstraZeneca's drug(s) in the clinic, then we might see a partnering deal on terms acceptable to Peregrine and long term shareholders. I guess that might take a year. So, I don't see any worthwhile partnering for a while.

Until that time Peregrine must conserve cash by cutting non-Avid payroll IMO. This might help the share price crawl back above a dollar, and save us from a disastrous reverse split.

GLTA, Paul